Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study


Autoria(s): Cotter, Aoife G.; Vrouenraets, Saskia M. E.; Brady, Jennifer J.; Wit, Ferdinand W.; Fux, Christoph A.; Furrer, Hansjakob; Brinkman, Kees; Sabin, Caroline A.; Reiss, Peter; Mallon, Patrick W. G.
Data(s)

01/04/2013

Resumo

Context: In virologically suppressed, antiretroviral-treated patients, the effect of switching to tenofovir (TDF) on bone biomarkers compared to patients remaining on stable antiretroviral therapy is unknown. Methods: We examined bone biomarkers (osteocalcin [OC], procollagen type 1 amino-terminal propeptide, and C-terminal cross-linking telopeptide of type 1 collagen) and bone mineral density (BMD) over 48 weeks in virologically suppressed patients (HIV RNA < 50 copies/ml) randomized to switch to TDF/emtricitabine (FTC) or remain on first-line zidovudine (AZT)/lamivudine (3TC). PTH was also measured. Between-group differences in bone biomarkers and associations between change in bone biomarkers and BMD measures were assessed by Student's t tests, Pearson correlation, and multivariable linear regression, respectively. All data are expressed as mean (SD), unless otherwise specified. Results: Of 53 subjects (aged 46.0 y; 84.9% male; 75.5% Caucasian), 29 switched to TDF/FTC. There were reductions in total hip and lumbar spine BMD in those switching to TDF/FTC (total hip, TDF/FTC, −1.73 (2.76)% vs AZT/3TC, −0.39 (2.41)%; between-group P = .07; lumbar spine, TDF/FTC, −1.50 (3.49)% vs AZT/3TC, +0.25 (2.82)%; between-group P = .06), but they did not reach statistical significance. Greater declines in lumbar spine BMD correlated with greater increases in OC (r = −0.28; P = .05). The effect of TDF/FTC on bone biomarkers remained significant when adjusted for baseline biomarker levels, gender, and ethnicity. There was no difference in change in PTH levels over 48 weeks between treatment groups (between-group P = .23). All biomarkers increased significantly from weeks 0 to 48 in the switch group, with no significant change in those remaining on AZT/3TC (between-group, all biomarkers, P < .0001). Conclusion: A switch to TDF/FTC compared to remaining on a stable regimen is associated with increases in bone turnover that correlate with reductions in BMD, suggesting that TDF exposure directly affects bone metabolism in vivo.

Formato

application/pdf

Identificador

http://boris.unibe.ch/44313/1/jc%252E2012-3686.pdf

Cotter, Aoife G.; Vrouenraets, Saskia M. E.; Brady, Jennifer J.; Wit, Ferdinand W.; Fux, Christoph A.; Furrer, Hansjakob; Brinkman, Kees; Sabin, Caroline A.; Reiss, Peter; Mallon, Patrick W. G. (2013). Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study. Journal of clinical endocrinology and metabolism, 98(4), pp. 1659-1666. Endocrine Society 10.1210/jc.2012-3686 <http://dx.doi.org/10.1210/jc.2012-3686>

doi:10.7892/boris.44313

info:doi:10.1210/jc.2012-3686

urn:issn:0021-972X

Idioma(s)

eng

Publicador

Endocrine Society

Relação

http://boris.unibe.ch/44313/

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Cotter, Aoife G.; Vrouenraets, Saskia M. E.; Brady, Jennifer J.; Wit, Ferdinand W.; Fux, Christoph A.; Furrer, Hansjakob; Brinkman, Kees; Sabin, Caroline A.; Reiss, Peter; Mallon, Patrick W. G. (2013). Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study. Journal of clinical endocrinology and metabolism, 98(4), pp. 1659-1666. Endocrine Society 10.1210/jc.2012-3686 <http://dx.doi.org/10.1210/jc.2012-3686>

Palavras-Chave #610 Medicine & health
Tipo

info:eu-repo/semantics/article

info:eu-repo/semantics/publishedVersion

PeerReviewed